Research Article
Effectiveness and Safety of Lianhua Qingwen Capsules for COVID-19: A Propensity-Score Matched Cohort Study
Table 1
Baseline characteristics of COVID-19 patients by Lianhua Qingwen use.
| | Characteristic | Overall (N = 4918) | Control (N = 2158) | LHQW (N = 2760) | -Value |
| | Age (years) | 61.0 (49.0-69.0) | 59.0 (47.0-68.0) | 62.0 (51.0-69.0) | <0.001 |
| | Gender (%) | | | | 0.054 | | Female | 2377 (48.3) | 1077 (49.9) | 1300 (47.1) | | | Male | 2541 (51.7) | 1081 (50.1) | 1460 (52.9) | |
| | Time from symptom onset to admission (days) | 14.0 (7.0-27.0) | 16.0 (8.0-30.0) | 13.0 (7.0-20.0) | <0.001 | | Severity at admission (n, %) | | | | 0.138 | | Nonseverea | 2771 (56.3) | 1242 (57.6) | 1529 (55.4) | | | Severeb | 2147 (43.7) | 916 (42.4) | 1231 (44.6) | |
| | Symptoms at admission (n, %) | | Fever | 2763 (56.2) | 1110 (51.4) | 1653 (59.9) | <0.001 | | Cough | 1969 (40.0) | 764 (35.4) | 1205 (43.7) | <0.001 | | Dyspnea | 1279 (26.0) | 532 (24.7) | 747 (27.1) | 0.060 | | Fatigue | 1278 (26.0) | 500 (23.2) | 778 (28.2) | <0.001 | | Diarrhea or vomiting | 1059 (21.5) | 457 (21.2) | 602 (21.8) | 0.615 |
| | Comorbidities (n, %) | | Diabetes | 796 (16.2) | 370 (17.1) | 426 (15.4) | 0.115 | | Hypertension | 1430 (29.1) | 601 (27.8) | 829 (30.0) | 0.100 | | Cancer | 45 (0.9) | 20 (0.9) | 25 (0.9) | 1.000 | | Heart diseases | 306 (6.2) | 133 (6.2) | 173 (6.3) | 0.927 |
| | Medication (n, %) | | Antiviral | 3778 (76.8) | 1378 (63.9) | 2400 (87.0) | <0.001 | | Adrenocortical hormone | 1447 (29.4) | 666 (30.9) | 781 (28.3) | 0.054 | | Anticoagulant | 657 (13.4) | 350 (16.2) | 307 (11.1) | <0.001 |
|
|
LHQW, Lianhua Qingwen capsules; aincluding mild and moderate cases. bincluding severe and critical cases.
|
